腹水超滤浓缩回输腹腔术治疗肝硬化顽固性腹水疗效分析

目的 探讨腹水超滤浓缩回输腹腔术治疗肝硬化顽固性腹水的疗效。方法 将56例肝硬化顽固性腹水患者随机分为2组,均给予保肝、利尿及抗病毒治疗。在此基础上,对治疗组行腹水超滤浓缩回输腹腔术加小剂量人血白蛋白静脉滴注(静滴)(每滤出1000ml腹水,静滴人血白蛋白4g),对对照组行大量放腹水加大剂量人血白蛋白静滴(每抽出1000ml腹水,静滴人血白蛋白8g)。结果 术后第14天,治疗组患者24h尿量、血清ALB水平均高于对照组(P均<0.05),且治疗组总有效率高于对照组(P<0.05)。结论 腹水超滤浓缩回输腹腔术是一种安全有效的治疗肝硬化顽固性腹水的方法。

Efficacy of ascitic ultrafiltration with intraperitoneal reinfusion of the concentrated ascites on refractory ascites in patients with liver cirrhosis

Objective To investigate the efficacy of ascitic ultrafiltration with intraperitoneal reinfusion of the concentrated ascites on refractory ascites in patients with liver cirrhosis. Methods Totally 56 cirrhotic patients with refractory ascites were ran- domized into a treatment group and a control group. The patients in the two groups received conventional therapy including hepato- protective, diuretic and antiviral therapy. In addition, the treatment group underwent ascitic ultrafiltration with intraperitoneal reinfusion of the concentrated ascites and intravenous infusion of a small dose of human serum ALB ( 4 g for every 1000 ml of ascitic fluid removed), while the control group received large volume paracentesis and intravenous infusion of a large dose of human serum ALB ( 8 g for every 1000 ml of ascitic fluid removed). Results After 14 days of treatment, the 24-hour urine volume and serum ALB level in the treatment group were higher than those in the control group (P<0.05). The total effective rate in the treatment group was higher than that in the control group (P <0.05). Conclusion Ascitic ultrafiltration with intraperitoneal reinfusion of the concentrated as cites is safe and effective in the treatment of refractory ascites in cirrhotic patients.